Distinct mutational pattern of Myelodysplastic syndromes with and without 5q- treated with lenalidomide. Adema V, Palomo L, Toma A, Kosmider O, Fuster-Tormo F, Benito R, Salgado R, Such E, Larrayoz MJ, Xicoy B, Hernandez-Sanchez JM, Maietta P, Neef A, Fontenay M, Ibañez M, Diez Campelo M, Alvarez A, Maciejewski JP, Fenaux P, Sole F. Br J Haematol. 2020 May;189(4):e133-e1.

Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. Marta Martín-Izquierdo 1, María Abáigar 1, Jesús M Hernández-Sánchez 1, David Tamborero 2, Félix López-Cadenas 3, Fernando Ramos 4, Eva Lumbreras 1, Andrés Madinaveitia-Ochoa 5, Marta Megido 6, Jorge Labrador 7, Javier Sánchez-Real 4, Carmen Olivier 8, Julio Dávila 9, Carlos Aguilar 10, Juan N Rodríguez 11, Guillermo Martín-Nuñez 12, Sandra Santos-Mínguez 1, Cristina Miguel-García 1, Rocío Benito 1, María Díez-Campelo 13, Jesús M Hernández-Rivas 14..Haematologica. 2020 Jul 16;haematol.2020.248807. doi: 10.3324/haematol.2020.248807. Online ahead of print.

The implication of ‘unknown significance’ variants in next‐generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene. Bernardo López‐Andrade Leyre Bento Maria Diez Campelo Félix López Cadenas Teresa González Martín Laura Lo Riso Andres Novo Jorge Martinez‐Serra Carmen Ballester Antonia Sampol Maria Antonia Duran.British Journal of Haematology, 2020, 189, e119–e187

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Nat Med. 2020 Aug 3. doi: 10.1038/s41591-020-1008-z. Epub ahead of print. PMID: 32747829

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G.Leukemia. 2020 Jun 29. doi: 10.1038/s41375-020-0917-7. Epub ahead of print. PMID: 32595214.

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Elena Crisà 1 2 3, Austin G Kulasekararaj 4, Vera Adema 5 6, Esperanza Such 7 8, Julie Schanz 9, Detlef Haase 9, Katayoon Shirneshan 9, Steven Best 10, Syed A Mian 4 11, Aytug Kizilors 10, José Cervera 12, Nicholas Lea 10, Dario Ferrero 13 14, Ulrich Germing 15, Barbara Hildebrandt 16, Ana Belén Valencia Martínez 17, Valeria Santini 13 17, Guillermo F Sanz 7 8 18, Francesc Solé 5, Ghulam J Mufti 4. Leukemia. 2020 Sep;34(9):2441-2450.

Cancer Testis Antigens in Myelodysplastic Syndromes Revisited: a Targeted RNA-seq Approach. Ana María Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Salvador Carrillo-Tornel, Joaquín Panadero, Eduardo José Salido, Victor Beltrán, Begoña Muiña, MariLuz Amigo, Noelia Navarro-Villamor, Rosa Cifuentes, Inés Calabria, Ana Isabel Antón, Raúl Teruel, Manuel Muro, Vicente Vicente, Andrés Jerez. OncoImmunology, in press, Accepted_10/09/2020

Host immune genetic variations influence the risk of developing acute myeloid leukaemia: Results from the NuCLEAR consortium.

José Manuel Sánchez-Maldonado, Daniele Campa, Jan Springer, Jon Badiola, Yasmeen Niazi, Ana Moñiz-Díez, Francisca Hernández-Mohedo, Pedro González-Sierra, Rob ter Horst, Angelica Macauda, Stefanie Brezina, Cristina Cunha, Michaela Lackner, Miguel López-Nevot, Luana Fianchi, Livio pagano, Elisa López-Fernández, Leonardo Potenza, Mario Luppi, Lucía Moratalla, Juan José Rodríguez-Sevilla, Joao Fonseca, Mar Tormo Diaz, Carlos Solano, Esther Clavero, Antonio Romero, Yang Li, Cornelia Lass-Flörl, Hermann Einsele, Lourdes Vazquez, Jurgen Loeffler, Kari Hemminki, Agostinho Carvalho, Mihai Netea, Andrea Gsur, Charles Dumontet, Federico Canzian, Asta Försti, Manuel Jurado, Juan Sainz.

Longer genetically determined telomeres are associated with increased risk of developing myeloproliferative neoplasms.

Matteo Giaccherini, Angelica Macauda, Nicola Sgherza, Juan Sainz, Federica Gemignani, José Maldonado, Manuel Jurado, Francesca Tavano, Grzegorz Mazur, Andrés Jerez, Joanna Góra-Tybor, Aleksandra Gołos, Francisca Hernández-Mohedo, Joaquin Martinez-Lopez, Judit Várkonyi, Raffaele Spadano, Aleksandra Butrym, Daniele Campa, Federico Canzian.

Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

Angelica Macauda, Matteo Giaccherini, Juan Sainz, Federica Gemignani, Nicola Sgherza, José Manuel Sánchez-Maldonado, Joanna Gora-Tybor, Joaquin Martinez-Lopez, Gonzalo Carreño-Tarragona, Andrés Jerez, Raffaele Spadano, Aleksandra Gołos, Manuel Jurado, Francisca Hernández-Mohedo, Grzegorz Mazur, Francesca Tavano, Aleksandra Butrym, Judit Várkonyi, Federico Canzian, Daniele Campa.

Estudio de alteraciones autoinmunes en pacientes con SMD.

Annal of Hematology

Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.

Caballero JC1, Sánchez Barba M2, Hernández Sánchez JM3, Such E4, Janusz K3, Sanz G4, Cabrero M1, Chillón C5, Cervera J4, Hurtado AM6, Jerez A6, Calderón Cabrera C7, Valcárcel D8, Lumbreras E3, Abáigar M3, López Cadenas F1, Hernández Rivas JM1,3, Del Cañizo MC1,9, Díez Campelo M10,11.Ann Hematol. 2019 Sep;98(9):2151-2162. doi: 10.1007/s00277-019-03751-6. Epub 2019 Jul 16

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology.

Bastida JM, López-Godino O, Vicente-Sánchez A, Bonanad-Boix S, Xicoy-Cirici B, Hernández-Sánchez JM, Such E, Cervera J, Caballero-Berrocal JC, López-Cadenas F, Arnao-Herráiz M, Rodríguez I, Llopis-Calatayud I, Jiménez MJ, Del Cañizo-Roldán MC, Díez-Campelo M.Int J Lab Hematol. 2019 Feb;41(1):109-117. doi: 10.1111/ijlh.12933. Epub 2018 Oct 5. PMID: 30290085

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Palomo L1, Ibáñez M2,3,4, Abáigar M5, Vázquez I6,7, Álvarez S8, Cabezón M9, Tazón-Vega B10,11, Rapado I12,13,14, Fuster-Tormo F1, Cervera J2,3,15, Benito R5, Larrayoz MJ6,7, Cigudosa JC8, Zamora L9, Valcárcel D10,11, Cedena MT12,13,14, Acha P1, Hernández-Sánchez JM5,16, Fernández-Mercado M6,17,18, Sanz G2,3, Hernández-Rivas JM5,16,19, Calasanz MJ6,7, Solé F1, Such E2,3,4; Spanish Group of MDS (GESMD).AID – BJH16175. Manuscript ID – BJH-2019-00857.R1.Br J Haematol. 2020 Mar;188(5):605-622. doi: 10.1111/bjh.16175. Epub 2019 Oct 16.

Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.

Montes P, Bernal M, Campo L.N, González Ramírez A.R, Jiménez P, Garrido P, Jurado M, Garrido F, Ruiz-Cabello F, Hernández, F.Cancer Immunol Immunother. 2019 Dec;68(12):2015-2027. doi: 10.1007/s00262-019-02420-x. Epub 2019 Nov 8.

The importance of adequate recognition of normal and dysplastic myelopoiesis for the diagnosis of myelodysplastic syndromes.

Lourdes Florensa*, Leonor Arenillas*, Xavier Calvo*, Encarnación Pérez-Vila, Sara Montesdeoca, Ana Ferrer and Soledad Woessner, Escola de Citologia Hematològica Soledad Woessner-Parc de Salut Mar, Laboratorio de Citología Hematológica, Patología, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain *contributed equally to this work. Histol Histopathol (2019) 34: 857-873

Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.Paola Montes, Martin Kerick, Mónica Bernal, Francisca Hernández.

Oncotarget. 2018; 9:36929-36944

CD34(+) Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, ​ Valcárcel D ​ , Solano C, López-Corral L, Sierra J, Perales MA.
Biol Blood Marrow Transplant. 2018 Jan 2. pii: S1083-8791(17)31839-6. doi: 10.1016/j.bbmt. 2017.12.804. [Epub ahead of print]

Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P.
Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15190. [Epub ahead of print] PubMed PMID: 29611196.

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.
Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D.
Am J Hematol. 2018 Mar 25. doi: 10.1002/ajh.25089. [Epub ahead of print]

Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D.
Ann Hematol. 2018 Mar 23. doi: 10.1007/s00277-018-3302-0. [Epub ahead of print]

DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, García O, Fuster-Tormo F, Grau J, Feliu E, Solé F, Buschbeck M, Zamora L.
Epigenetics. 2018;13(1):8-18.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.
Int J Mol Sci. 2017;18(4). pii: E837. doi: 10.3390/ijms18040837.

Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in Myelodysplastic Syndromes and Permits a Better Definition of the Intermediate Risk Category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ana F, Sanz GF, Florensa L; Grupo Español de Síndromes Mielodisplásicos (GESMD)
Am J Hematol. 2017;92(7):614-621.

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J.
Oncotarget. 2017;8(63):106948-106961. doi: 10.18632/oncotarget.22157.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.
de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.
Ann Hematol. 2017;96(7):1105-1112.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.
Blood. 2017;129(13):1753-1762.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.
Leuk Res. 2017;52:1-7.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.
J Hematol Oncol. 2017;10(1):131.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts.
Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.
Leukemia. 2017;31(12):2799-2806.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.
Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.
Biol Blood Marrow Transplant. 2017;23(6):971-979.

Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.
Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O’Connor JE, Sáez GT, Carbonell F, Collado R.
Clin Biochem. 2017;50(16-17):911-917.

A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M,Valiente A, Robledo C, Benito R, Díez-Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM.
Leuk Res. 2017;56:82-7.

Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis.
Montoro J, Robledo C, Zamora L, Valcárcel D, Ramos F.
Ann Hematol. 2017;96(2):317-8.

Excess mortality in the myelodysplastic syndromes.
Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group.
Am J Hematol. 2017;92(2):149-54.

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M,Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.
Leuk Res. 2017;63:85-89.

Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D.
Exp Hematol. 2017;48:1-11.

Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.
Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M.
Genes Chromosomes Cancer. 2017;56(3):243-252.

Inspecting targeted deep sequencing of whole genome amplified DNA versus fresh DNA for somatic mutation detection: A genetic study in myelodysplastic syndrome patients.
Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, Haro N, Mallo M, Xicoy B, Zamora L, Solé F.
Biopreserv Biobank. 2017;15(4):360-365.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
J Clin Oncol. 2017;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271.

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bourhis JH, Raj K, von dem Borne PA, Sica S, Menard AL, Bloor A, Kenzey C, Gluckman E, Rocha V.
Br J Haematol. 2017;179(5):790-801.

Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.
Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M.
Eur J Cancer Care (Engl). 2017;26(6). doi: 10.1111/ecc.12426.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).
Am J Hematol. 2017;92(9):E534-E541.

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L,Sánchez-Del-Real J, Alonso JM, Cuello R, Megido M, Rodríguez JN, Martín-Núñez G, Aguilar C, Vargas M, Martín AA, García JL, Kohlmann A, Del Cañizo MC, Hernández-Rivas JM.
PLoS One. 2016;11(10):e0164370.doi:10.1371/journal.pone.0164370. eCollection 2016.

Considering Bone Marrow Blasts From Non-Erythroid Cellularity Improves The Prognostic Evaluation Of Myelodysplastic Syndrome.
Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Diez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L; on behalf of Grupo Español de Síndromes mielodisplásicos (GESMD).
J Clin Oncol. 2016;34(27):3284-92.

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future MDS classifications.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo C, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L; on behalf of Grupo Español de Síndromes Mielodisplásicos (GESMD).
Mod Pathol. 2016;29(12):1541-51.

Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.
Costa D, Muñoz C, Carrió A, Arias A, Gómez C, Solé F, Espinet B, Azaceta G, Calasanz MJ, Nomdedeu M, Calvo X, Campo E, Nomdedeu B.
Acta Haematol. 2016;135(2):94-100.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.
Blood. 2016; 128(16):2096-7.

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
Nomdedeu M, Calvo X, Pereira A, Carrió A, Solé F, Luño E, Cervera J, Vallespí T, Muñoz C, Gómez C, Arias A, Such E, Sanz G, Grau J, Insunza A, Calasanz MJ,Ardanaz MT, Hernández-Rivas JM, Azaceta G, Álvarez S, Sánchez J, Martín ML, Bargay J, Gómez V, Cervero CJ, Allegue MJ, Collado R, Campo E, Esteve J, Nomdedeu B, Costa D; Spanish Group of Myelodysplastic Syndromes.
Genes Chromosomes Cancer. 2016;55(4):322-7.

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP.
Leukemia. 2016;30(12):2405-9.

Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L.
Am J Hematol. 2016;91(2):185-92.

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L.
Oncotarget. 2016;7(35):57021-35.

Time-dependent changes in mortality and transformation risk in MDS.
Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.
Blood. 2016;128(7):902-10.

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, García-Ruiz de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Spanish Group for Myelodysplastic Syndromes (GESMD).
Oncotarget. 2016;7(21):30492-30503.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.
Eur J Haematol. 2016;97(1):33-8.